Actively Recruiting
Phase III Study Comparing Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab to Chemotherapy Plus Pembrolizumab for HER2-Expressing, Mismatch Repair Proficient Advanced or Recurrent Endometrial Cancer
Led by AstraZeneca · Updated on 2026-10-13
600
Participants Needed
257
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of trastuzumab deruxtecan T-DXd combined with either rilvegostomig or pembrolizumab compared to chemotherapy plus pembrolizumab in treating women with HER2-expressing, mismatch repair proficient, advanced or recurrent endometrial cancer. This Phase III randomized study aims to assess progression-free survival PFS as its primary outcome, with additional measures including overall survival and treatment safety. Participants are assigned to one of three treatment groups Arm A receives T-DXd and rilvegostomig intravenously every three weeks Arm B receives T-DXd and pembrolizumab intravenously every three weeks Arm C receives carboplatin, paclitaxel, and pembrolizumab every three weeks for six cycles followed by pembrolizumab maintenance every six weeks for up to 20 cycles. Treatment continues until disease progression or other discontinuation criteria are met. Docetaxel may replace paclitaxel if necessary due to allergic reactions. During the study, participants will undergo various assessments including imaging to monitor disease progression according to RECIST criteria, safety evaluations, pharmacokinetic and immunogenicity testing, and patient-reported tolerability measures. These assessments occur throughout treatment and up to approximately 70 months for survival and safety follow-up. The study involves regular monitoring by independent review and investigator assessments to evaluate treatment effects and patient outcomes.
CONDITIONS
Brief Title
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here